https://www.eastbaytimes.com/2023/04/27/biogen-receives-fda-approval-for-breakthrough-als-treatment-pivotal-moment-in-als-research/

Massachusetts-based Biogen has gotten the green light for a breakthrough ALS treatment that targets a devastating, ultra-rare genetic form of the progressive neurodegenerative disease.

The U.S. Food and Drug Administration on Tuesday granted approval of Qalsody for the treatment of ALS in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. Biogen’s treatment is the first approved treatment to target a genetic cause of ALS.